Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek

PII: S2211-0348(21)00701-X
DOI: https://doi.org/10.1016/j.msard.2021.103435
Reference: MSARD 103435

To appear in: Multiple Sclerosis and Related Disorders

Received date: 7 October 2021
Revised date: 16 November 2021
Accepted date: 27 November 2021

Please cite this article as: Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek, Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod, Multiple Sclerosis and Related Disorders (2021), doi: https://doi.org/10.1016/j.msard.2021.103435

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V.
Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

Magdalena Krbot Skorić1,2, Dunja Rogić3, Ivana Lapić3, Dragana Šegulja3, Mario Habek1,4

1 Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia
2 Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia
3 Clinical Institute for Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia
4 School of Medicine, University of Zagreb, Zagreb, Croatia

Corresponding author:
Mario Habek, MD, PhD
Department of Neurology, University Hospital Center Zagreb
Kišpatićeva 12
HR-10000 Zagreb
Croatia
Phone/Fax: +38512388033; e-mail: mhabek@mef.hr

Word count: 787
Number of references: 15
Number of tables: 1
Number of figures: 1

Authors’ contributions
Study concept and design: Habek. Acquisition of data: Krbot Skorić, Rogić, Lapić, Šegulja, Habek. Analysis and interpretation of data: Krbot Skorić, Rogić, Lapić, Šegulja, Habek. Drafting of the manuscript: Habek. Critical revision of the manuscript for important intellectual content: Krbot Skorić, Rogić, Lapić, Šegulja, Habek. Administrative, technical, and material support: Krbot Skorić, Rogić, Lapić, Šegulja, Habek.

Financial & competing interest disclosure
MKS: received consultation and/or speaker fees from: Sanofi Genzyme, Roche.
DR: Reports no conflict of interest.
IL: Reports no conflict of interest.
DŠ: Reports no conflict of interest.
MH: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals.

Funding:
No funding was received for this study.
E-mails:
Magdalena Krbot Skorić, mkrbot@gmail.com
Dunja Rogić, predstojnik.lab@kbc-zagreb.hr
Ivana Lapić, ilapic@kbc-zagreb.hr
Dragana Šegulja, dse gulja@kbc-zagreb.hr
Mario Habek, mhabek@mef.hr

Key words: secondary progressive multiple sclerosis, siponimod, COVID-19, vaccines, SARS-CoV-2 IgG antibody

Introduction
Compared to relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) is characterized by older age, higher level of disability, and higher occurrence of cardiovascular comorbidities. (1) This is of particular importance in the light of COVID-19 pandemics, as real-world studies published so far identified age and cardiovascular comorbidities as independent risk factors for poor COVID-19 outcomes, with level of neurological disability and progressive multiple sclerosis (MS) phenotypes additionally increasing this risk. (3–5) More and more data also suggest an attenuated humoral response after SARS-CoV-2 infection and after COVID-19 vaccination in people with RRMS, depending on the disease modifying therapies used. (6–7)

As of recently, Siponimod—a sphingosine 1-phosphate receptor modulator—has been approved for the treatment of the active SPMS. (8) As limited data exist on response to vaccination in people with SPMS (pwSPMS) treated with siponimod, the aim of this study is to determine a development of humoral response after COVID-19 vaccination in pwSPMS on siponimod, compared to healthy controls (HC).

Methods
In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19. Elecsys® Anti-SARSCoV-2 S assay (Roche Diagnostics Int, Rotkreuz, Switzerland) was used per the manufacturer’s instructions, (9) using Cobas e 801 analytical unit for immunoassay tests (F. Hoffmann-La Roche Ltd.). Antibody titer ≥0.8 U/mL was considered positive, as recommended by the manufacturer (The WHO International Standard for COVID-19 serological tests conversion factor (BAU/mL) = 1.288; 1U/mL equals 1.288 BAU/ml (10)). All pwSPMS treated in our center, who were on treatment with siponimod for at least 6 months and who received both doses of COVID-19 vaccine, were invited to participate during their monthly visits to the clinical—administrative visits due to siponimod reimbursement. HC were aged and sex matched healthcare workers who received both doses of COVID-19 vaccine, without any neurological or immune related condition.

The study was approved by the Ethical Committee of the University Hospital Center, Zagreb (02/21 AG).

Statistical analysis was performed with the IBM SPSS v25 software. The data distribution was tested with the Kolmogorov-Smirnov test. The differences between qualitative variables were tested with the Chi-square test. The differences between the quantitative variables
were tested with the parametric independent sample t-test and non-parametric Mann-Whitney test. P-values less than 0.05 were considered significant.

Results

Demographic characteristics, vaccination status, and SARS-CoV2 IgG titer after vaccination are presented in Table 1. pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p<0.001) (Figure 1). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.

Discussion

This study has shown blunted humoral response after COVID-19 vaccination in pwSPMS on siponimod. Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator, which binds with high affinity to both S1P receptors 1 and 5. Its effects on MS are a consequence of reduction of the lymphocyte count, which may lead to compromised immune response function and thus potentially limit the effectiveness of vaccinations. In a randomized, placebo-controlled study, siponimod treatment had no relevant effect on antibody response to Pneumococcal vaccination. However, blunted humoral response was seen after Influenza vaccination. While no data on response to COVID-19 vaccination are available so far for pwSPMS on siponimod, several publications have shown blunted antibody response to COVID-19 vaccinations in fingolimod treated patients. In the study by Achiron and colleagues, only 1 out of 26 participants (pwMS treated with fingolimod) had an antibody response that was above the cut-off value for a positive response. In another study, pwMS treated with S1P receptor modulator had lower median SARS-CoV2 IgG index, compared to pwMS receiving other or no DMT. Furthermore, one study has shown that Spikevax® vaccine elicits 3.25-higher antibody response compared to Comirnaty® vaccine, suggesting that Spikevax® vaccine may be preferentially considered for patients under fingolimod. Despite all these studies showing blunted humoral response in patients treated with S1P receptor modulators, one should bear in mind that the majority of pwMS on these therapies make an unremarkable recovery from COVID-19, implying that innate and T-cell responses are functional. Based on this, these patients are likely to benefit from protective or at least partially protective T-cell responses to the vaccine. Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod. These results may have significant implications for management of pwSPMS in the light of the recent EMA update of 3rd dose mRNA COVID-19 vaccines in people with weakened immune systems. As a personal opinion of the authors, in all pwSPMS treated with siponimod, 3rd dose of the Comirnaty® or Spikevax® should be recommended.
References


Tables

<table>
<thead>
<tr>
<th></th>
<th>pwSPMS (N=13)</th>
<th>HC (N=11)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (females)</td>
<td>5 (38.5%)</td>
<td>3 (27.3%)</td>
<td>0.679</td>
</tr>
<tr>
<td>Age (years)</td>
<td>52.8±9.7</td>
<td>50.7±9.9</td>
<td>0.604</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>21.5±9.8</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>EDSS (median, range)</td>
<td>6.5 (3.0-7.0)</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Treatment duration (months)</td>
<td>14.5±6</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vaccination characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comirnaty®</td>
<td>8</td>
<td>9</td>
<td>0.298</td>
</tr>
<tr>
<td>Spikevax®</td>
<td>3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vaxzevria®</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Time between vaccination and blood sampling (days)</td>
<td>93.5±41.8</td>
<td>73.1±42.9</td>
<td>0.252</td>
</tr>
<tr>
<td><strong>Vaccination response</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SARS-CoV2 IgG titer (U/mL) median (range)</td>
<td>19.4 (0-250)</td>
<td>250 (250)</td>
<td>p&lt;0.001</td>
</tr>
</tbody>
</table>

Table 1. Demographic characteristics, vaccination status and SARS-CoV2 IgG titer after vaccination.

Figures

Figure 1. SARS-CoV-2 IgG antibody titer after COVID-19 vaccination in pwSPMS on siponimod and HC.